Anti-inflammatory and Anti-cancer Activity of Mulberry (Morus Alba L.) Root Bark
Overview
Affiliations
Background: Root bark of mulberry (Morus alba L.) has been used in herbal medicine as anti-phlogistic, liver protective, kidney protective, hypotensive, diuretic, anti-cough and analgesic agent. However, the anti-cancer activity and the potential anti-cancer mechanisms of mulberry root bark have not been elucidated. We performed in vitro study to investigate whether mulberry root bark extract (MRBE) shows anti-inflammatory and anti-cancer activity.
Methods: In anti-inflammatory activity, NO was measured using the griess method. iNOS and proteins regulating NF-κB and ERK1/2 signaling were analyzed by Western blot. In anti-cancer activity, cell growth was measured by MTT assay. Cleaved PARP, ATF3 and cyclin D1 were analyzed by Western blot.
Results: In anti-inflammatory effect, MRBE blocked NO production via suppressing iNOS over-expression in LPS-stimulated RAW264.7 cells. In addition, MRBE inhibited NF-κB activation through p65 nuclear translocation via blocking IκB-α degradation and ERK1/2 activation via its hyper-phosphorylation. In anti-cancer activity, MRBE deos-dependently induced cell growth arrest and apoptosis in human colorectal cancer cells, SW480. MRBE treatment to SW480 cells activated ATF3 expression and down-regulated cyclin D1 level. We also observed that MRBE-induced ATF3 expression was dependent on ROS and GSK3β. Moreover, MRBE-induced cyclin D1 down-regulation was mediated from cyclin D1 proteasomal degradation, which was dependent on ROS.
Conclusions: These findings suggest that mulberry root bark exerts anti-inflammatory and anti-cancer activity.
Widely Targeted Metabolomics Analysis to Reveal Metabolite of L. in Different Medicinal Parts.
Wang X, Qian Y, Wei M Molecules. 2024; 29(17).
PMID: 39274829 PMC: 11395776. DOI: 10.3390/molecules29173981.
Morus alba: a comprehensive phytochemical and pharmacological review.
El-Saber Batiha G, Al-Snafi A, Thuwaini M, Teibo J, Shaheen H, Akomolafe A Naunyn Schmiedebergs Arch Pharmacol. 2023; 396(7):1399-1413.
PMID: 36877269 PMC: 10244279. DOI: 10.1007/s00210-023-02434-4.
Sericultural By-Products: The Potential for Alternative Therapy in Cancer Drug Design.
Baci G, Baciu E, Cucu A, Musca A, Giurgiu A, Moise A Molecules. 2023; 28(2).
PMID: 36677907 PMC: 9861160. DOI: 10.3390/molecules28020850.
Han S, Kim H, Lee M, Lee J, Ahn K, Ha I Int J Mol Sci. 2022; 23(23).
PMID: 36499154 PMC: 9740770. DOI: 10.3390/ijms232314826.
Chavda V, Patel A, Mistry K, Suthar S, Wu Z, Chen Z Front Oncol. 2022; 12:867655.
PMID: 35425710 PMC: 9004605. DOI: 10.3389/fonc.2022.867655.